SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-304460"
 

Search: onr:"swepub:oai:DiVA.org:uu-304460" > Long-term evaluatio...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ezekowitz, Michael D.Thomas Jefferson Univ, Sidney Kimmel Med Coll, 1999 Sproul Rd, Philadelphia, PA 19107 USA.;Lankenau Med Ctr, Wynnewood, PA USA. (author)

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-03-03
  • Oxford University Press (OUP),2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-304460
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-304460URI
  • https://doi.org/10.1093/europace/euv312DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Aims The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial allowed patients who completed the trial receiving their assigned dabigatran 150 mg (D150) or 110 mg (D110) twice a day to continue into the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial. This permitted assessment of outcomes over a median of 4.6 and a maximum of 6.7 years, respectively. Methods and results The analysed population included only those patients who completed RE-LY on dabigatran and continued into RELYABLE without interruption of assigned dabigatran. Cumulative risk was expressed as Kaplan-Meier plots. Outcomes were compared using Cox proportional hazard modelling. Stroke or systemic embolization rates were 1.25 and 1.54% per year (D150 and D110, respectively); hazard ratio (HR) 0.81 [95% confidence interval (CI): 0.68-0.96] (P = 0.02). Ischaemic stroke was 1.03 (D150) and 1.29%/year (D110); HR 0.79 (95% CI: 0.66-0.95) (P = 0.01). Haemorrhagic stroke rates were 0.11 (D150) and 0.13%/year (D110); HR 0.91 (95% CI: 0.51-1.62) (P = 0.75). Rates of major haemorrhage were 3.34 (D150) and 2.76%/year (D110); HR 1.22 (95% CI: 1.08-1.37) (P = 0.0008). Intracranial haemorrhage rates were 0.32 (D150) and 0.23%/year (D110); HR 1.37 (95% CI: 0.93-2.01) (P = 0.11). Mortality was 3.43 (D150) and 3.55%/year (D110); HR 0.97 (95% CI: 0.87-1.08) (P = 0.54). Conclusion Annualized rates of all outcomes were constant with better efficacy of D150, less major bleeding with D110, and low intracerebral haemorrhage rates for both doses. There were no additional safety concerns. This is the longest continuous randomized experience of a novel anticoagulant.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Eikelboom, JohnMcMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada. (author)
  • Oldgren, JonasUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)jonaoldg (author)
  • Reilly, Paul A.Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA. (author)
  • Brueckmann, MartinaBoehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.;Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany. (author)
  • Kent, Anthony P.Thomas Jefferson Univ, Sidney Kimmel Med Coll, 1999 Sproul Rd, Philadelphia, PA 19107 USA. (author)
  • Pogue, JaniceMcMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada. (author)
  • Spahr, JudithLankenau Inst Med Res, Wynnewood, PA USA. (author)
  • Clemens, AndreasBoehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. (author)
  • Noack, HerbertBoehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. (author)
  • Diener, Hans-ChristophUniv Hosp Essen, Dept Neurol, Essen, Germany. (author)
  • Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)larswall (author)
  • Yusuf, SalimMcMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada. (author)
  • Connolly, Stuart J.McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada. (author)
  • Thomas Jefferson Univ, Sidney Kimmel Med Coll, 1999 Sproul Rd, Philadelphia, PA 19107 USA.;Lankenau Med Ctr, Wynnewood, PA USA.McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada. (creator_code:org_t)

Related titles

  • In:Europace: Oxford University Press (OUP)18:7, s. 973-9781099-51291532-2092

Internet link

Find in a library

  • Europace (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view